Invesaro

Stocks Comparison

Pennant vs GeneDx: revenue, profit, margins and growth compared

Pennant brought in $947.7M of revenue in fiscal 2025, GeneDx $427.5M in fiscal 2025. Revenue changed by +36.3% at Pennant and +40.0% at GeneDx on the year before, so GeneDx grew faster. Pennant kept 3.1% of its revenue as net profit, GeneDx -4.9%. Free cash flow was $36.3M at Pennant and $14.3M at GeneDx.

Side by side, latest fiscal year

PNTGWGS
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$947.7M$427.5M
Revenue growth+36.3%+40.0%
Net income$29.6M-$21M
Net margin3.1%-4.9%
Free cash flow$36.3M$14.3M
Free cash flow margin3.8%3.3%
Earnings per share (diluted)$0.84-$0.73
Cash$17M$105M
Debt$168.8M$54.5M
Price to earnings48.5n/a
Market value$1.4B$2.6B
Dividend yieldn/an/a
Rank by revenue in sector#148 of 523 · Health care#199 of 523 · Health care

Over the years

Revenue
PNTG FY2019: $286.1MPNTG FY2019: $338.5MPNTG FY2020: $391MPNTG FY2021: $439.7MPNTG FY2022: $473.2MPNTG FY2023: $544.9MPNTG FY2024: $695.2MPNTG FY2025: $947.7MWGS FY2019: $196.2MWGS FY2020: $179.3MWGS FY2021: $212.2MWGS FY2022: $234.7MWGS FY2023: $202.6MWGS FY2024: $305.5MWGS FY2025: $427.5MFY19FY20FY21FY22FY23FY24FY25
PNTG $947.7MWGS $427.5M
Net income
PNTG FY2019: $15.7MPNTG FY2019: $2.5MPNTG FY2020: $15.7MPNTG FY2021: $2.7MPNTG FY2022: $6.6MPNTG FY2023: $13.4MPNTG FY2024: $22.6MPNTG FY2025: $29.6MWGS FY2019: -$29.7MWGS FY2020: -$241.3MWGS FY2021: -$245.4MWGS FY2022: -$549MWGS FY2023: -$175.8MWGS FY2024: -$52.3MWGS FY2025: -$21MFY19FY20FY21FY22FY23FY24FY25
PNTG $29.6MWGS -$21M
Net margin
PNTG FY2019: 5.5%PNTG FY2019: 0.8%PNTG FY2020: 4.0%PNTG FY2021: 0.6%PNTG FY2022: 1.4%PNTG FY2023: 2.5%PNTG FY2024: 3.2%PNTG FY2025: 3.1%WGS FY2019: -15.1%WGS FY2020: -134.6%WGS FY2021: -115.6%WGS FY2022: -233.9%WGS FY2023: -86.8%WGS FY2024: -17.1%WGS FY2025: -4.9%FY19FY20FY21FY22FY23FY24FY25
PNTG 3.1%WGS -4.9%
Revenue growth
PNTG FY2019: +18.3%PNTG FY2020: +15.5%PNTG FY2021: +12.5%PNTG FY2022: +7.6%PNTG FY2023: +15.1%PNTG FY2024: +27.6%PNTG FY2025: +36.3%WGS FY2020: -8.6%WGS FY2021: +18.3%WGS FY2022: +10.6%WGS FY2023: -13.7%WGS FY2024: +50.8%WGS FY2025: +40.0%FY19FY20FY21FY22FY23FY24FY25
PNTG +36.3%WGS +40.0%
Free cash flow
PNTG FY2019: $19.7MPNTG FY2019: $2.8MPNTG FY2020: $43MPNTG FY2021: -$24.5MPNTG FY2022: -$5.1MPNTG FY2023: $25MPNTG FY2024: $30.3MPNTG FY2025: $36.3MWGS FY2019: -$30.7MWGS FY2020: -$117.2MWGS FY2021: -$199.8MWGS FY2022: -$326.3MWGS FY2023: -$185.4MWGS FY2024: -$34MWGS FY2025: $14.3MFY19FY20FY21FY22FY23FY24FY25
PNTG $36.3MWGS $14.3M

Fiscal years as each company reports them; the two may end in different months.

Questions about Pennant and GeneDx

Which is bigger by revenue, Pennant or GeneDx?

Pennant is bigger by revenue: $947.7M in fiscal 2025, against $427.5M for GeneDx in fiscal 2025.

Which keeps more of its revenue as profit, Pennant or GeneDx?

Pennant had a net margin of 3.1% in fiscal 2025; GeneDx had -4.9% in fiscal 2025.

Which grew revenue faster, Pennant or GeneDx?

In their latest fiscal years revenue changed by +36.3% at Pennant and +40.0% at GeneDx.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies